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1. Introduction 
Plant carbohydrates are crucial biomass polymers that we 
either use directly or process into other products. They are an 
important source of food and feed ingredients, and constitute 
a feedstock for bio-based materials and fuels.[1–3] Plant 
glycans show an extraordinary diversity and complexity 
leading to a variety of biological functions as well as physical 
properties.[4,5] A major class of highly complex 
polysaccharides in plant cell walls are pectins, which can be 
classified into three types: homogalacturonan (HG) and 
rhamnogalacturonan (RG) I and II. RG-I is a heteropolymer 
with a backbone of alternating α-linked L-rhamnose and 
D-galacturonic acid residues with extensive branching of 
galactans, arabinogalactans and arabinans.[4,5] Biological 
studies of individual polysaccharides in plant organs and 
plant-derived materials are immensely challenging due to 
their heterogeneity and diversity. Structurally defined 
oligosaccharides are useful tools as models for the more 
complex glycan polymers and can be used in investigations of 
a range of processes, such as cell wall biosynthesis and 
degradation as well as protein-carbohydrate interactions in 
general.  
Monoclonal antibodies with epitopes found in cell wall 
polysaccharides are important tools for studying plant glycans 
in situ with immunofluorescence microscopy. For example, 
this technique has been applied to determine changes in cell 
wall polysaccharide distributions during plant 
development.[6,7] The frequently used rat monoclonal antibody 
LM5 is known to bind β-1,4-linked galactans.[8] LM5 has 
been applied in immunohistochemical analysis, 
immunofluorescence microscopy, live cell labeling and for 
glycan microarray screening.[8–11] The antibody was generated 
by immunization of rats with a β-1,4-Gal4-BSA 
neoglycoprotein. It has been reported that for LM5-binding at 
least four consecutive β(1→4) galactosyl units are required as 
previous studies indicated no interaction with β-1,4-galacto-
biose and –triose.[8] Furthermore, we have previously shown 
that LM5 does not tolerate β-1,6 branching in order to bind to 
defined galactans.[12] We were interested in more detailed 
insight into the binding mode of LM5. From previous work, it 
was not clear whether the non-reducing end of linear β-1,4-
galactans is part of the LM5 epitope. In order to answer this 
question, we designed three β-1,4-tetragalactoside analogues 
1-3 (Figure 1). In the three synthetic oligosaccharides, the 
axial C4-OH in the non-reducing end residue was replaced 
with C4-F, C4-OMe and the C4-epimer, respectively. We 
envisioned that by either replacing the C4 hydroxy group with 
the bioisosteric fluorine, blocking it by methylation or 
changing the orientation by making the gluco-analogue, we 
would be able to learn more about the LM5 epitope. 
The chemical synthesis of β-1,4-D-galactans can be 
problematic due to low reactivity of the axially disposed 
C4-OH of the corresponding galactosyl acceptors. Thus, few 
approaches have been reported so far.[13–15] Our group recently 
published a convergent strategy for the synthesis of linear and 
branched β(1→4)-D-galactans.[12] This approach inspired our 
pursuit of the three different analogues required for studying 
the LM5 epitope.  
2. Results and Discussion 
It was intended to synthesize the analogues with the building 
blocks 7-11 shown in Figure 1. Thereby, N-
phenyltrifluoroacetimidate donors could be reacted with 
pentenyl glycosides as acceptors. Pentenyl glycosides where 
chosen as intermediates, due to their stability under 
methylation and fluorination conditions.  
 
A R TI C LE  IN FO  
A BS TRA C T 
Plant cell wall glycans are important polymers that are crucial to plant 
development and serve as an important source of sustainable biomass. The study 
of polysaccharides in the plant cell wall relies heavily on monoclonal antibodies 
for localization and visualization of glycans, using e.g. Immunofluorescent 
microscopy. Here, we describe the detailed epitope mapping of the mab LM5 that 
is shown to bind to a minimum of three sugar residues at the non-reducing end of 
linear beta-1,4-linked galactan. The study uses de novo synthetic analogs of 
galactans combined with carbohydrate microarray and competitive inhibition 
ELISA for analysis of antibody-carbohydrate interactions. 
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Figure 1: Retrosynthetic analysis of the desired tetragalactan 
analogues 1–3. 
 
Fluorinated galactoside 14 was prepared in four steps from the 
known pentenyl glucoside 12 (Scheme 1).[16,17] The common 
way of synthesizing fluorinated sugars is the use of 
diethylaminosulfur trifluoride (DAST).[18] Unfortunately, this 
method was not applicable for C4-F galactose analogues. 
Instead, the C4-OH of 13 was converted to the corresponding 
triflate and fluorine was introduced by an SN2 substitution 
with tetrabutylammonium fluoride (TBAF) to give 14 in 59% 
(over two steps). 
Scheme 1: a) i. BzCl, Et3N, DMAP, CH2Cl2, 89%, ii. Et3SiH/TFA, 
CH2Cl2, 74%; b) i. Tf2O, pyridine, CH2Cl2, ii. TBAF, CH2Cl2, 85% 
over two steps; c) i. NBS, MeCN/H2O (20:1), ii. 2,2,2-trifluoro-N-
phenylacetimidoyl chloride, Cs2CO3, CH2Cl2, 5 ˚C, 59% over two 
steps. 
 
The O-4 methylated pentenyl galactoside donor 17 was 
obtained in three steps from the known diol 15 (Scheme 2).[19] 
Alkylation of the C4-OH of 16 turned out to be challenging 
due to the low reactivity and the tendency of the neighboring 
benzoyl group to either migrate or undergo hydrolysis. A 
combination of Meerweins’s salt and Proton-sponge® gave 
smooth conversion to 17 in 84% yield without side product 
formation.[20] Unfortunately, neither pentenyl donor 14 nor 17 
could be used as donors, as they proved to have low reactivity 
and afford unsatisfactory coupling yields in glycosylation 
reactions. Instead, the pentenyl glycosides were converted to 
the more reactive imidate donors 7 and 8 in two steps. The 
perbenzoylated glucosyl imidate 9 was synthesized following 
a literature procedure.[16] 
Next step was the synthesis of the trisaccharide acceptor 22. 
Starting from pentenyl glycoside 15, regioselective 
benzylation of C3-OH was performed via the stannylene 
acetal in a yield of 79% (Scheme 3). Piv-protection of C2-OH 
afforded donor 10, which was transformed to galactosyl 
imidate 18 in two steps. 
 
Scheme 2: a) i. BzCl, Et3N, DMAP, CH2Cl2, 89 %, ii. Et3SiH/TFA, 
CH2Cl2, 0 ˚C, 72%; b) Me3OBF4, Proton sponge, CH2Cl2, 84%; c) i. 
NBS, MeCN/H2O (20:1), ii. 2,2,2-trifluoro-N-phenylacetimidoyl 
chloride, Cs2CO3, CH2Cl2, 0 ˚C, 74% over two steps. 
 
Acceptor 19 was obtained from 10 by regioselective opening 
of the benzylidene acetal with triethylsilane/trifluoroacetic 
acid (Et3SiH/TFA) in 80%.[21] The regioselectivity was 
validated by acetylating the liberated C4-OH, which resulted 
in a characteristic downfield shift from 3.98 ppm to 5.08 ppm 
of the H-4 proton in the NMR spectrum, whereas the H-6 
protons resonated at the same frequencies as for the starting 
material.[22,23]  
 
Scheme 3: a) i. Bu2SnO, then BnBr, CsF, toluene, 79%, ii. PivCl, 
Et3N, DMAP, CH2Cl2, 92 %; b) i. NBS, acetone/H2O (9:1), 2,6-
lutidine, 50 ˚C, ii. 2,2,2-trifluoro-N-phenylacetimidoyl chloride, 
Cs2CO3, CH2Cl2, 75% over two steps; c) Et3SiH/TFA, CH2Cl2, 80%. 
 
Trimethylsilyl trifluoromethanesulfonate (TMSOTf) catalyzed 
coupling of donor 18 and acceptor 19 afforded 
disaccharide 20 in an excellent yield of 81% (Scheme 4). 
Disaccharide 20 was used as donor in the following 
glycosylation of monosaccharide acceptor 11, synthesized 
according to Andersen et al.[12] After the glycosylation 
reaction, the pivaloyl groups were exchanged by benzyl ethers 
in a two-step procedure in 82% to give trisaccharide 21. This 
maneuver was elected, because we were concerned that the 
relatively harsh basic conditions needed for deesterification 
could lead to elimination of hydrogen fluoride for the 
fluorinated analogue. Regioselective opening of the 
benzylidene acetal of 21 proved challenging. No conversion 
was observed upon treatment with NaCNBH3/HCl[24] or 
NaCNBH3/I2[25], whereas Et3SiH/TFA[21] and 
Et3SiH/Cu(OTf)2[26] only resulted in slow hydrolysis. Instead, 
the acetal was hydrolyzed with ethanethiol and p-
toluenesulfonic acid (p-TSA) followed by a selective 
acetylation of C6-OH to yield 22 (Scheme 4). 
 
 Scheme 4: a) TMSOTf, CH2Cl2, -40 ˚C, 81%; b) i. 11, 
NIS/TESOTf, CH2Cl2/MeCN (1:1), -40 ˚C, 86%, ii. KOH, DMSO, 
iii. BnBr, NaH, TBAI, DMF, 82% over two steps; c) i. ethanethiol, 
p-TSA, CH2Cl2, 94%, ii. Ac2O, Et3N, CH2Cl2, 88%. 
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TMSOTf-catalyzed glycosylation of acceptor 22 with the 
three donors 7-9 afforded the corresponding tetrasaccharides 
4, 5 and 6 in good yields of 74-78% (Scheme 5). The 
experiments were performed under identical reactions 
conditions in dichloromethane with 5% TMSOTf as promoter. 
The three reactions were allowed to reach 0 ˚C, since no 
conversion was observed at lower temperatures. The 
methylated donor 8 reacted faster (2.5 h to full conversion) 
than the electron-poor, fluorinated galactoside 7 and the 
glucoside 9 (4 h to full conversion for donors 7 and 9).  
Scheme 5: a) TMSOTf, CH2Cl2, -20 ˚C → 0 ˚C; b) i. NaOMe, 
MeOH, ii. H2, Pd(OH)2, MeOH, THF.   
 
Transesterification with sodium methoxide in methanol 
followed by hydrogenolysis with Pearlman’s catalyst gave the 
unprotected target molecules 1, 2 and 3 (Scheme 5). In order 
to remove traces of Pd(OH)2/C, purification by C18 reverse-
phase column chromatography on C18-modified silica was 
necessary. 
 
The compounds 1-3 were printed and analyzed using 
microarrays as described previously.[12] The result of the 
microarray analysis is shown in Table 1. The galactans β-1,4-
D-Gal3 and β-1,4-D-Gal4, previously synthesized in our lab, 
were used as controls.[27] β-1,4-D-Gal4 was used to normalize 
the signals (highest fluorescence intensity set at 100). The 
controls showed interaction with LM5, but not with LM6. 
LM6 is an antibody with high affinity against α-1,5-L-Ara and 
was used as control. We have previously shown that LM5 
does not tolerate branching when binding to galactans and that 
introduction of arabinose as the terminal, non-reducing end 
residue precludes binding.[12] According to the original report, 
LM5 requires at least four consecutive galactose units to 
bind.[8] Surprisingly, we could see binding with the 
trisaccharide β-1,4-D-Gal3. This result shows that three 
galactose units are enough for antibody recognition. Binding 
studies with the three synthesized analogues 1-3 showed 
noteworthy differences. Moderate intensity was detected with 
C4-F galactan 1. As an isostere of the β-1,4-D-Gal4 similar 
binding behavior was expected and could be seen even though 
lesser in intensity than β-1,4-D-Gal4. Similar results were seen 
with the methylated galactan 2. It was proposed that 
methylation will block the C4 position and thus hinder the 
antibody binding. That could not be confirmed. Interestingly, 
no binding was detected with the epimeric analogue 3. This 
result suggest that the non-reducing end residue of the 
galactans is a pivotal part of the binding epitope. The 
configuration at the terminal C4 appears to be important for 
the LM5-binding, which explains the similar behavior of the 
fluorinated and methylated analogues 1 and 2 compared to 
epimeric analogue 3. 
Table 1: Binding of LM5 monoclonal antibody to galactan 
analogues 1-3 and linear galactans (β-1,4-D-Gal3/4) on microarray; 
LM6 antibody (affinity to α-1,5-L-Ara) was used as a control.  
  Antibody 
Galactan LM5 LM6 
β-1,4-D-Gal3 55 0 
β-1,4-D-Gal4 100 0 
1 – C4-F  34 0 
2 – C4-OMe  31 0 
3 – C4-epimer 0 0 
α-1,5-L-Ara4 0 36 
 
In order to confirm that the non-reducing end residue of the 
galactans is recognized by LM5, we designed a competitive 
inhibition enzyme-linked immunosorbent assay (ciELISA) 
experiment to demonstrate that the presence of a higher 
concentration of smaller oligosaccharides more effectively 
inhibited the binding of LM5 to an immobilized antigen. 
Firstly, lupin galactan was titrated in the soluble phase to 
determine its capacity to inhibit binding of LM5 to 
immobilized antigen (lupin galactan) and 20 µg/ml was 
chosen as the amount to act as soluble galactan inhibitor. In 
order to increase the ratio of non-reducing ends in the 
solution, in a set of separate tubes the soluble galactan was 
hydrolyzed with a range of concentrations of endo-β-1,4-
galactanase for 15 min at 37 °C. Reactions were stopped by 
heating at 95 °C for 5 min and samples were then decanted to 
act as the soluble phase in LM5 ciELISAs. Figure 2 shows 
that at low enzyme concentrations enzyme-treated galactan 
was a more effective inhibitor than the untreated sample, 
demonstrating a higher capacity for binding to LM5. 
Increasing the enzyme concentration leads to less inhibition, 
this is due to degradation to β-1,4-D-Gal2, which is not 
recognized by LM5. These data confirm the microarray 
results by illustrating a higher inhibitory effect from the 
presence of a higher concentration of smaller galactans. 
Figure 2: LM5 ELISA showing capacity of the pre-treatment of 
20 µg/ml lupin galactan (soluble galactan) with a range of endo-β-
1,4-galactanase concentrations to modulate LM5 binding to 
immobilized antigen. At low concentrations of enzyme the inhibitory 
capacity of soluble galactan increases. Means and SD of three 
independent experiments shown.   
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In conclusion, the synthetic oligosaccharide microarrays and 
enzyme-ciELISAs indicate that LM5 recognition of pectic 
1,4-galactans by LM5 requires a non-reducing end residue 
and that LM5 does not bind to internal regions of linear 
galactans. This extended understanding of the LM5 epitope 
has implications for the interpretation of LM5 binding in in 
situ analyses and other immunoassays.  
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